Mineralys Therapeutics, Inc. - Common Stock (MLYS)
27.33
+0.00 (0.00%)
NASDAQ· Last Trade: Aug 12th, 8:29 AM EDT
Detailed Quote
Previous Close
27.33
Open
-
Bid
26.95
Ask
27.33
Day's Range
N/A - N/A
52 Week Range
12.59 - 47.65
Volume
20,895
Market Cap
-
PE Ratio (TTM)
-9.264
EPS (TTM)
-3.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
634,801
Chart
About Mineralys Therapeutics, Inc. - Common Stock (MLYS)
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of cardiovascular and metabolic diseases. The company specializes in discovering and commercializing novel therapeutics that target mineralocorticoid receptors, a pathway that plays a significant role in regulating blood pressure and fluid balance. Through its cutting-edge research and development efforts, Mineralys aims to improve patient outcomes and enhance quality of life by providing effective solutions for conditions related to hypertension and related disorders. Read More
Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen
When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.
A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain; after a year of tech-led mega caps setting new highs, investors have clearly shown an increased appetite for risk in the form of smaller, lesser known names.
